China healthcare Report Interpretation

Overview

This 1H26 results review finds that China healthcare’s rally, initially led by innovators, is broadening across several subsectors. J.P. Morgan retains a strong sector view into 2H26, emphasizing earnings durability, clinical catalysts, global licensing and NRDL negotiations.

Core views

China healthcare outperformed sharply: the MSCI China Healthcare Index rose 33% over the past three months while the broader MSCI China Index was flat. The report attributes this to rotation toward defensive sectors, earnings beats and guidance increases, enthusiasm for AI-driven drug discovery (AIDD), and continued globalization. Innovative-drug outlicensing deals reached US$110bn in 1H26. The central question for 2H26 is whether earnings growth can remain sustainable; J.P. Morgan expects major clinical readouts, globalization activity and NRDL negotiations to influence the next leg of performance. Its preferred subsectors are Biotech, CXO and AIDD, while diagnostics and TCM are least preferred. Biotech remained the strongest subsector for top-line growth, but the report stresses that profits are now becoming meaningful as well. Innovent’s product sales rose 57% year on year and non-IFRS net profit increased 40%, exceeding market expectations. Kelun Biotech’s product sales rose more than 100%, supporting potential recurring net profit in FY27E; Junshi recorded its first profitable half-year; and RemeGen’s core business was roughly breakeven in 2Q excluding business-development income. The report links this progress to a favorable environment for innovative drugs, scaled commercial capabilities, operating leverage and cost discipline. However, Akeso and Ascentage missed 1H26 revenue expectations, showing that NRDL coverage and clinical efficacy alone no longer guarantee commercial success. CXO entered a growth-acceleration phase, driven by domestic demand recovery and sustained global demand. WuXi AppTec’s new orders rose more than 40%; WuXi Biologics’ order growth accelerated to 23% on a constant-FX basis and it raised guidance; Pharmaron and Tigermed each reported roughly 30% order growth. WuXi AppTec, WuXi Biologics and Pharmaron raised FY26 revenue guidance mid-year as orders converted into revenue. WuXi XDC maintained guidance despite a record backlog, up 50% year on year, because capacity constraints precede new-facility ramp-ups. The report sees margin expansion from operating leverage, a richer complex-molecule mix and more late-stage or commercial projects. GenScript is highlighted as AIDD demand becomes tangible business demand, with related revenue potentially doubling in 2H26; Tigermed’s clinical-CRO recovery is slower, although contract pricing has begun to improve. The report is watching the potential end-2026/early-2027 list of “Biotechnology Companies of Concern.” AIDD shifted from a narrative to monetization. Insilico’s revenue rose 287% year on year to US$106mn and it earned US$35.5mn of net profit, supported by licensing deals with Lilly, Servier and Takeda worth roughly US$7.3bn year to date; J.P. Morgan estimates FY26 revenue of around US$180-190mn, while noting that deal timing is lumpy. XtalPi’s AI4S infrastructure revenue rose 136% and accounted for half of group sales. Metis reported 133x revenue growth from a low base and signed a global licensing deal for MTS-128 with up to US$1.6bn in milestones plus a US$20mn upfront. The report’s conclusion is that AIDD platforms are increasingly producing licensable drug assets rather than only providing R&D services. Among Big Pharma, commercialization execution increasingly differentiates companies. Hansoh reported revenue growth of 11.7%, with innovative-drug sales and collaboration income comprising 85% of sales; domestic innovative-product sales grew 21.6% and adjusted net profit rose 19%. Its roadmap calls for five new innovative-drug launches next year and 30 by 2030. Hengrui missed expectations in 2Q as certain first-generation products faced NRDL renewal price cuts and tougher competition, and management lowered the implied FY26 innovative-drug growth bar from about 30% through its ESOP. Licensing is becoming a recurring earnings contributor: Hansoh booked about Rmb1.1bn in Roche and Regeneron upfronts and has US$9bn-plus of signed deal value since 2023, while Hengrui is due to recognize a BMS upfront in 3Q26. Recovery elsewhere is uneven but broadening. Healthcare services remain constrained by soft consumption, though traffic improved in 2Q26. Aier’s reported profit decline was largely a Rmb756mn back-tax provision, while its refractive and optometry businesses grew modestly; overseas revenue reached 14% of sales and Brazil consolidates in 3Q. Gushengtang’s revenue grew 10.6%, but mix shifted toward lower-ticket consumer healthcare; it is pivoting toward M&A and overseas expansion. MedTech growth is led by overseas markets: Mindray’s international sales rose 13.7%, or 18.4% in US-dollar terms, while United Imaging’s overseas revenue rose 54.5% to 25% of sales. Domestic trends are beginning to bottom, but pricing and RMB appreciation continue to pressure margins. Pharmacies delivered a traffic-led recovery. Dashenlin’s 2Q revenue growth accelerated to 6.9% from 0.3% in 1Q and recurring net profit rose 26.2%; Yifeng’s same-store sales accelerated to about 6%; and Laobaixing’s mature-store sales grew more than 5% in 2Q and 9% in July. Industry exits are returning customers to surviving stores, while profits depend on margin discipline and cost control because ticket sizes remain flat and discretionary non-drug sales are weak. Franchise and M&A models are expanding, and innovative drugs and GLP-1 products offer upside through traffic and assortment diversification. Diagnostics are stabilizing through cost control rather than volume growth: KingMed and Dian returned to profit as margins improved or impairment charges fell, despite low-single-digit revenue declines. TCM remained the weakest subsector: only 24 of 68 listed A-share TCM companies grew revenue, and 2Q net profit fell 24% year on year versus a 5.5% decline in 1Q. Destocking, VBP expansion and soft discretionary demand drove the weakness. Still, the report identifies trough signals in herbal-material prices down about 17% year on year, expected margin recovery as high-cost inventory clears, and 48 TCM products added to the essential-drug list in September.

Analysis framework

The report reviews 1H26 earnings and operating indicators across China healthcare subsectors, comparing revenue, profit, orders, guidance, commercial execution, overseas demand and policy developments. It then identifies sector-specific drivers and 2H26 clinical, regulatory and globalization catalysts.

Methodology notes

• Industry AnalysisVolume-price decomposition

  The report distinguishes traffic, ticket size, pricing, sales volume, margins and cost control.

  This separates revenue recovery driven by customer traffic or product mix from recovery driven by pricing, and distinguishes profit improvement from volume-led growth.

• Corporate Fundamentals and FinanceOperating and Financial Leverage Analysis

  Operating leverage and cost discipline are used to explain improving biotech and CXO profitability.

  The report links scale, mix improvement and controlled costs to profit conversion as revenue expands.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  The report traces demand from drug innovation and licensing activity to CXO orders, AIDD platforms and pharmacy channels.

  It uses supply-chain linkages to explain how innovation, commercialization and global demand affect different healthcare subsectors.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China healthcare sector

  The report views the sector as a growth and defensive diversification opportunity into 2H26.

  Strengths

  Broadening earnings recovery, global licensing, clinical catalysts and defensive-sector rotation.

  Weaknesses

  Recovery remains uneven across consumer-sensitive and domestic-demand segments.

  Comparison

  Biotech, CXO and AIDD are preferred; diagnostics and TCM are least preferred.

  Risks

  Sustainable earnings growth, pricing pressure and policy or regulatory developments remain key variables.

• Biotech

  Preferred subsector supported by growth and emerging profitability.

  Strengths

  Commercial scale, operational leverage, cost discipline and licensing activity.

  Weaknesses

  Clinical efficacy and NRDL coverage do not assure revenue delivery.

  Comparison

  The strongest subsector for top-line growth in 1H26.

  Risks

  Commercial execution risk and uneven revenue delivery.

• CXO

  Preferred subsector in a growth-acceleration phase.

  Strengths

  Broadening orders, raised guidance, global demand and improving mix.

  Weaknesses

  Capacity constraints at WuXi XDC and slower clinical-CRO recovery at Tigermed.

  Comparison

  More favored than diagnostics and TCM.

  Risks

  Potential “Biotechnology Companies of Concern” list and capacity timing.

• AIDD

  Preferred subsector as platforms monetize through licensing and asset creation.

  Strengths

  Rapid revenue growth, profitability and large licensing transactions.

  Weaknesses

  Revenue can be lumpy because deal timing is irregular.

  Comparison

  Has moved from thematic interest to business demand.

  Risks

  Licensing timing and execution risk.

Key data

• MSCI China Healthcare Index+33%Past three months; broader MSCI China Index was flat.
• Innovative-drug outlicensing valueUS$110bnTotal deal value in 1H26.
• Innovent product sales+57% YoY1H26; non-IFRS net profit rose 40%.
• WuXi AppTec new orders+40%+1H26; part of broad CXO order recovery.
• Insilico revenueUS$106mn, +287% YoY1H26; net profit was US$35.5mn.
• United Imaging overseas revenue+54.5%1H26; overseas accounted for 25% of sales.
• TCM 2Q net profit-24% YoYVersus -5.5% in 1Q, based on Wind data.

Impact & implications

J.P. Morgan sees a more diversified China healthcare recovery entering 2H26, with innovative-drug profitability, CXO order conversion and AIDD asset monetization offering the strongest support. Commercial execution, domestic demand normalization, pricing pressure and forthcoming clinical and policy catalysts will determine whether the recovery persists.

Risks

• Commercial success for innovative drugs may not follow automatically from NRDL coverage and clinical efficacy.
• CXO capacity constraints and slower clinical-CRO pricing recovery may delay growth conversion.
• RMB appreciation and domestic pricing pressure continue to weigh on MedTech margins.
• Potential end-2026/early-2027 designation of “Biotechnology Companies of Concern” is being monitored.
• Soft consumption, VBP expansion and destocking continue to constrain parts of healthcare services and TCM.

What to watch

• Major clinical readouts at WCLC and ESMO.
• Globalization activity and innovative-drug licensing transactions.
• 2026 NRDL negotiations and renewals.
• CXO order-to-revenue conversion, new-facility ramp-ups and FY26 guidance delivery.
• Domestic MedTech tender activity and margin trends in 2H26.
• Pharmacy traffic, innovative-drug and GLP-1 sales, and M&A/franchise expansion.